NEWS AND ANNOUNCEMENTS
MailOnline — 6 October 2014
Painless X-ray that can save failing
eyes in 15 minutes

A radiotherapy treatment could drastically reduce the need for regular injections. Biographer and historian Jonathan Gathorne-Hardy, 81, from Binham, Norfolk, had the procedure. More >

Oraya Therapetics Named Among Fierce Medical Devices 2014 Fierce 15


What is Fierce Medical Devices Fierce 15? Fierce Medical Devices takes a look at some of the most promising private med tech companies. More >

What makes Oraya Therapeutics Fierce? Oraya’s novel device for treating wet age-related macular degeneration reduces the number of injections needed to treat the condition. More >

Three-year Data from INTREPID Study Shows Favorable Safety Profile — Commercial Adoption of Oraya Therapy Continues to Grow.

Full results of three-year safety follow-up data from the INTREPID study of Oraya Therapy™ for wet age-related macular degeneration (AMD) further demonstrated a favorable safety profile and also showed that there was no significant difference in vision outcomes in patients treated with Oraya Therapy compared with those receiving anti-vascular endothelial growth factor (anti-VEGF) injections alone.
More >

Oraya Therapy Expansion Release

home_map

The Oraya Therapy is now available in Germany, Switzerland and the United Kingdom. Additional locations coming soon. For more information, call 0800-690-6495 in the United Kingdom and in Germany call 0800-283-2243.

TreatmentCenters_sm

Oraya Therapy Centers
BBC Look North – September 2014

 
BBC-LookNorth-clip

Press Release: First National Health Service hospital in UK and four prestigious hospitals in Germany adopt Oraya Therapy to maintain vision with reduced anti-VEGF injections.
More >

News-Medical.net – September 2014

 
News-Medical-Net

Treating wet AMD with gold nanoparticles: an interview with Jim Taylor, CEO, Oraya Therapeutics More >

————————————————

Published Articles
Stereotatic Radiotherapy for Wet Age-Related Macular Degeneration (INTREPID): Influence of Baseline Characteristics on Clinical Response

Published ahead of print, RETINA, August 2014. Download >

Treating Neovascular AMD

Published in Expert Reviews of Ophthalmology, 2014. Download >

INTREPID Study One Year Results

Published in Ophthalmology, September 2013. Download >

WHAT IS AMD?

Age-Related Macular Degeneration (AMD) is a progressive disease that causes loss of central vision leading to blindness. It is the primary cause of vision loss for seniors in the industrialized world. While there is no cure for AMD, the Oraya Therapy™ for Wet AMD is an exciting new treatment.   More >

WHO IS ORAYA?

Founded in 2007, Oraya® Therapeutics, Inc. is a privately held company developing an innovative and non-invasive therapy designed to advance the treatment options for wet AMD.  More >

WHY ORAYA THERAPY?

Physicians and patients require a new option and a new vision for the treatment of wet AMD. Oraya Therapy— intended as a one-time, non-invasive procedure—uses a low-voltage, stereotactic approach. It delivers precisely controlled X-rays confined to the diseased area of interest, sparing the surrounding structures of the eye.  More >

© 2014 All rights reserved to Oraya Therapeutics The IRay® Radiotherapy System is an investigational device and is not available for sale in the U.S.A. Oraya, Oraya Therapy, IRay and I-Guide are either trademarks or registered trademarks of Oraya Therapeutics, Inc. in the United States and other countries.